MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Mirum Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product sales, net | $521.31M | $336.41M | $178.87M | $75.06M | $3.14M | $0 | 100.0% | +55.0% |
| Livmarli | $360.01M | $213.30M | $141.80M | $75.06M | $3.14M | – | 69.1% | +68.8% |
| Bile Acid Medicines | $161.31M | $123.11M | $37.08M | $0 | $0 | – | 30.9% | +31.0% |
| License and other revenue | $0 | $479.00K | $7.50M | $2.00M | – | – | 0.0% | -100.0% |
| License | – | – | $7.50M | $2.00M | $16.00M | $0 | – | – |
| License revenue | – | – | $7.50M | $2.00M | $16.00M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Mirum Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.